Second Genome Announces Inflammatory Bowel Disease Research Alliance with the APC Microbiome Institute at University College Cork

April 27, 2015, South San Francisco, CA

Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, has entered into an alliance with the Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC), Ireland, to advance the development of therapies that prevent and treat inflammatory bowel disease (IBD). Scientists from both groups will partner to explore the role of the microbiome in IBD by analyzing data from patients to identify new opportunities for therapeutic intervention.

Read More

Second Genome Advances Lead Microbiome Drug Development Program in Phase I Clinical Trial as a Treatment for Inflammatory Bowel Disease

January 12, 2015, South San Francisco, CA

Second Genome, Inc., a pioneer in the development of novel medicines through innovative microbiome science, announced today that the company is advancing its lead drug candidate, SGM-1019, into a Phase I multiple-ascending dose clinical trial for the treatment of inflammatory bowel disease. SGM-1019 inhibits a target that Second Genome researchers discovered to be a key driver of inflammatory bowel disease when modulated by changes in the microbiome.

Read More

Second Genome and Mayo Clinic Enter Collaboration to Develop Microbiome Therapeutics in Multiple Diseases

October 7, 2014, South San Francisco, CA

Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, has entered into an extensive partnership with the Mayo Clinic Center for Individualized Medicine to support the development of therapeutic products for multiple disease indications, starting with inflammatory bowel disease, metabolic disorders, and colorectal cancer.

Read More

Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Scientific Officer

September 9, 2014, South San Francisco, CA

Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has appointed Karim Dabbagh, Ph.D., as the company’s Chief Scientific Officer. In this new position, Dr. Dabbagh will be responsible for the company’s drug pipeline, fueled by Second Genome’s novel discovery platform for identifying and validating microbiome-mediated drug targets and therapeutics.

Read More

Second Genome Enters Into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity

May 2, 2014, South San Francisco, CA

Second Genome announced today that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes, in order to better understand the inter-relationship between the microbiome, obesity and metabolic disorders.

Read More

Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis

June 5, 2013, San Bruno, CA

Second Genome, Inc. announced today that the company has entered into an agreement with Janssen Biotech, Inc. (Janssen) focused on microbiome drug discovery. With the goal of advancing novel drug targets, the agreement is focused on therapeutic mechanisms in ulcerative colitis mediated by the bacterial ecosystem living within the human gut, referred to as the microbiome. Second Genome will apply its microbiome modulation discovery platform to characterize the role of bacterial populations in ulcerative colitis.

Read More

Second Genome Sponsors American Gut Initiative to Identify Links Between Type 2 Diabetes and the Human Microbiome

January 3, 2013, San Francisco, CA

Second Genome announced today an initiative with the American Gut project to explore the connection between the human microbiome and type 2 diabetes. The cooperation will bring together American Gut's broad citizen science network for microbiome sample collection with Second Genome's efforts in identifying microbiome modulators and novel therapeutics. Second Genome has made an undisclosed donation to American Gut to subsidize specimen collection for participants with type 2 diabetes.

Read More

Second Genome Presents Preclinical Research on the Impact of the Microbiome on C. difficile Infection

November 2, 2012, San Bruno, CA

Second Genome announced today new research demonstrating the impact that commensal or healthy bacteria have on the ability of the gut microbiome, the diverse population of microbes that inhabit the intestinal flora, to prevent against C. difficile infection. Preclinical data demonstrated a correlation between time from disruption to restoration of the microbiome and the ability for C. difficile to grow. These findings suggest that promotion of growth and rehabilitation of the gut microbiome may help close the window of susceptibility to C. difficileinfection.

Read More